Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Nadolol × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1 Gastrointestinal 1

Conditions

Liver Cirrhosis 1 Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 1211 Fluorouracil 1128 Capecitabine 929 Gemcitabine 897 Leucovorin 803 Irinotecan 701 Bevacizumab 682 Cisplatin 576 Radiotherapy 477 Cetuximab 401 pembrolizumab 367 Paclitaxel 334 Nivolumab 282 Drug Therapy 273 130-nm albumin-bound paclitaxel 267 Docetaxel 259 S 1 (combination) 243 Sorafenib 239 Folfox protocol 226 Albumin-Bound Paclitaxel 210 durvalumab 186 Surgical Procedures, Operative 181 apatinib 178 tislelizumab 170 lenvatinib 170 Radiosurgery 170 sintilimab 168 Carboplatin 159 Radiation 152 regorafenib 151

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00567216 2010-06-08

GVO-nadolol

Taipei Veterans General Hospital, Taiwan

Phase 4 Unknown

Gastrointestinal

Carcinoma, Hepatocellular, Liver Cirrhosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡